百亿市值脑机接口龙头被警示

Core Viewpoint - The article discusses the regulatory warning issued to Entropy Technology by the Guangdong Securities Regulatory Bureau due to five major violations related to financial reporting and disclosures, which could impact the company's reputation and operations [1][2][3]. Summary by Sections Regulatory Violations - Entropy Technology received a warning letter from the Guangdong Securities Regulatory Bureau for five key violations: inaccurate revenue recognition, improper bad debt provision, incorrect R&D expense accounting, inaccurate inventory impairment provision, and inadequate disclosure of related party transactions [1][2]. - Specifically, the company recognized revenue of 369,500 yuan in 2024 that was not aligned with the corresponding sales period due to inconsistent rebate periods for certain customers [1]. - The company failed to adequately provision for bad debts, particularly for clients with significant credit risk, relying solely on aging categories rather than individual assessments [1]. - R&D expenses were inaccurately reported as they included salaries of non-R&D personnel without proper documentation of their project hours [1]. Inventory and Related Party Transactions - The inventory impairment provision was inaccurately calculated, as the company used a sales expense rate of 15% from a different subsidiary instead of the actual 57% from ZKTECOUSALLC, leading to an overestimation of net realizable value [2]. - There was a discrepancy in the disclosure of related party transactions, with the actual sales amount to ZKTECO SOLUTIONS INC. being 18.91 million yuan, significantly higher than the reported 11.34 million yuan [2]. Company Response and Market Position - The company and its executives are required to take corrective actions and submit a written report to the Guangdong Securities Regulatory Bureau within 30 days [3]. - Entropy Technology, listed on the Shenzhen Stock Exchange since August 2022, focuses on biometric technology and related applications, indicating a commitment to innovation despite current regulatory challenges [3]. - The company has been actively engaging with investors, holding three institutional research meetings recently, and plans to launch a brain-machine interface prototype by March 2026, although this is not expected to significantly impact short-term revenue [4]. - Financial results for the first three quarters of 2025 show a slight decline in revenue to 1.401 billion yuan, while net profit increased by 6.24% to 128 million yuan [4]. - The company's stock has seen a rise of over 37% this year, with a market capitalization of 10.6 billion yuan as of January 12 [4].